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Fragments based on the VEGFR2i Semaxanib (SU5416, (vascular endothelial growth factor receptor-2
inhibitor) and the HDACi (histone deacetylase inhibitor) SAHA (suberanilohydroxamic acid) have been
merged to form a range of low molecular weight dual action hybrids. Vindication of this approach is
provided by SAR, docking studies, in vitro cancer cell line and biochemical enzyme inhibition data as well
as in vivo Xenopus data for the lead molecule (Z)-N1-(3-((1H-pyrrol-2-yl)methylene)-2-oxoindolin-5-yl)-
N8-hydroxyoctanediamide 6.Introduction
Cancer treatment oen employs combinations, or cocktails, of
drugs to reduce resistance and improve eﬃcacy.1 Histone
deacetylase inhibitors (HDACis) are gaining importance in
anticancer therapy since they can alter the expression of a host
of important proteins and transcription factors.2,3 Indeed,
HDACis such as SAHA or valproate can be eﬀectively combined
with a number of anticancer agents, e.g. platinum-based,
Hsp90, kinase or proteasome inhibitors.4,5,5,6
VEGFR2 is secreted by tumour cells under hypoxic stress,
leading to angiogenesis. Antiangiogenic approaches include the
deployment of VEGFR2is or use of HDACis, which can down-
regulate the expression of angiogenesis-critical genes. PTK787/
ZK 222584, a VEGFR2i, was shown to have excellent VEGFR2
inhibition alone, yet synergized with the HDACi Dacinostat,
reducing angiogenesis, much more markedly than the separate
components in vivo (Fig. 1).7
A relatively new concept makes use of a chimeric, or hybrid,
drug where the separate components are linked together in oneGreenwich, Chatham, ME4 4TB, UK
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hemistry 2014novel entity.8 Such an approach may lead to improved synergy
and eﬃcacy, lower treatment costs (use of one instead of two
drugs), avoid dosing and drug–drug interaction issues as well as
generate new intellectual property. Indeed, reports of HDACi-
containing hybrid agents are increasing exponentially9–18and
include the SAHA-tarceva-like dual HDAC-kinase inhibitor 1,19
which has entered clinical trials, as well as the SAHA-sunitinib-
like hybrid 2 (Fig. 2).20
Given our interests in synthesizing SAHA21,22 and Semaxanib-
like molecules,23 this approach prompted us to consider
designing a HDACi/VEGFR2i, dual action hybrid related to 2,
although we were unfamiliar of the latter at the onset of our
project. Hence, preliminary attempts in this direction involved
the reaction of the amines 3 with acid chlorides 4, followed by
hydroxylamine treatment, aﬀording the hybrids 6 and 7. We
also synthesized the shorter chained compound 8 as well as the
diﬀerent benzamide zinc binding group (ZBG)-containing 9 and
10 (Scheme 1).Fig. 1 A VEGFR2i–HDACi combination leads to increased anticancer
eﬀects.
Fig. 2 Examples of hybrid anticancer agents in the prior art.
Med. Chem. Commun., 2014, 5, 1829–1833 | 1829
Scheme 1 Synthesis of hybrid molecules.
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View Article OnlineInitial docking studies predicted the hybrid molecule 6 to
display activity towards both kinase and HDAC targets (Fig. 3).
Upon binding to HDAC8, the hydroxamate group of 6 was found
to coordinate to the enzyme's zinc atom, with the kinase motif
being solvent-exposed. However, docking of the hybrid in the
VEGFR2 kinase domain is not straightforward, although it is
feasible for it to exploit the plasticity of the binding site. When
docked into the co-crystal structure of a sunitinib complex
(4agd), the kinase inhibitor moiety in 6 cannot adopt the
conformation observed in the known crystal structure.
However, a plausible binding pose is obtained when the hybrid
molecule is docked in an alternative VEGFR2 structure (4asd),
in which the binding pocket has an induced pocket. The latter
can accommodate the hydroxamate moiety while still retaining
the interactions of the sunitinib moiety. Hybrid 13 comfortably
ts in VEGFR2, helping to rationalise its potent kinase activity
(vide infra).Scheme 2 Aminocarbonylation routes to hybrids.
Fig. 3 Docking poses: (a) hybrid 6 in HDAC8 structure (pdb: 1t69): (b)
hybrid 6, (c) hybrid 13 in VEGFR2 kinase structure (pdb: 4asd).
1830 | Med. Chem. Commun., 2014, 5, 1829–1833Thioether-containing ZBG analogues were also synthesized
(Scheme 2). Hence, the regioisomeric “reverse” amides 13 and
14 were formed by microwave-mediated palladium catalysed
aminocarbonylations employing molybdenum hexacarbonyl as
a carbon monoxide source (Fig. 3).24–27
Both 6 and 7 were tested in biochemical assays against a
small number of kinases and compared with the library of
hybrids that we synthesized for SAR investigations (Table 1).
Hybrid 6 showed poor inhibition of the kinase c-kit when tested
at 10 mMconcentration yet submicromolar inhibition of three of
the four kinases tested (VEGFR1,2, PDGFRa,b).28,29 Hybrid 7 was
signicantly less eﬀective. Most of these analogues were less
eﬀective than the original hybrid 6, with the exception of
compound 8, which had improved activity against the two
VEGFR isoforms tested. Additionally, the thioether containing
hybrid 13 had potent nM kinase activity.
All of the above hybrids were tested versus whole cell HDACs
at 1 mM concentration using a uorimetric in vitro histone
deacetylase assay. Those that exhibited >20% inhibition, i.e. 6–
8, were tested in a dose-response assay with compound 6
comfortably displaying the best activity, albeit ten-fold less than
TSA (Trichostatin A) (Table 2).
Compound 6 also showed excellent HDAC inhibition in a
biochemical assay; hybrid 8 had comparable activity to SAHA,
which was used as a control, and the benzamides 9 and 10
tended to be signicantly less active than SAHA (Table 3). None
of the thioether containing hybrids showed any activity and
none of the hybrids had signicant HDAC4 or HDAC9 activity.31
The hybrids were tested in vivo, in Xenopus embryos, which
were exposed to increasing concentrations of compound and
assayed. The ability to inhibit HDAC activity was monitored by
assaying alpha tubulin acetylation levels, which showed 6 to beTable 1 Biochemical kinase inhibition data (n ¼ 2 unless speciﬁed). i.a.
¼ inactive. n.d. ¼ not determined, performed at Reaction Biology
Cpd
IC50;
VEGFR1
(nM)
IC50;
VEGFR2
(nM)
IC50;
PDGFRa
(nM)
IC50;
PDGFRb
(nM)
6 364.5  0.7 237  7 1187 (n ¼ 1) 185  13
7 i.a. i.a. i.a. i.a.
8 205  32 290  47 i.a. 518 (n ¼ 1)
9 i.a. i.a. i.a. i.a.
10 i.a. i.a. i.a. i.a.
13 i.a. 38  9 11.8  0.2 8.0  0.02
14 i.a. i.a. 245  15 i.a.
SU5416 (ref. 30) 43  11 220  34 n.d 68  2
Table 2 Cell-based HDAC inhibition studies
Cpd IC50 (nM) with SEM
6 117  29
7 443  15
8 935  29
TSA 12  1
This journal is © The Royal Society of Chemistry 2014
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Fig. 4 Sets of twelve 2-cell Xenopus laevis embryos were treated with
compound 6 (top) or SAHA (bottom) at the concentrations shown until
they developed to stage 14. Protein extracts equivalent to 1 embryo
were separated by duplicate SDS-PAGE gels and acetylated alpha-
tubulin or total alpha-tubulin were detected by Western blotting.
Fig. 5 Sets of 12 2-cell X. laevis embryos, treated with DMSO or
increasing mM concentrations of compound 6 at stage 9, allowed to
develop to stage 38, ﬁxed and Egﬂ7 mRNA levels determined by in situ
hybridisation.
Fig. 6 Dose–response curves for SAHA/3bmixture (open circles) and
hybrid drug (black circles) exposed for 72 h to MDA-MB231 breast
cancer cells. The results are expressed as mean  s.e.m of triplicate
assays.
This journal is © The Royal Society of Chemistry 2014
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View Article Onlinethe most eﬀective deacetylation inhibitor tested of the series,
even more eﬀective than SAHA. Hybrid 6 produced a maximal
deacetylation inhibition at the lowest concentration tested i.e.
10 uM (Fig. 4).Med. Chem. Commun., 2014, 5, 1829–1833 | 1831
Table 4 NIH cell panel assay for hybrid 6
Panel Cell line GI50
a (nM)
Leukemia CCRF-CEM 102
HL-60(TB) 477
K-562 251
MOLT-4 302
RPMI-8226 2920
SR 296
NSCLc A549/ATCC 2905
HOP-62 381
HOP-92 412
NCI-H226 2320
NCI-H23 1320
NCI-H322M 1017
NCI-H460 2745
NCI-H522 87
Colon COLO 205 248
HCC-2998 1635
HCT-116 238
HCT-15 4590
HT29 612
KM12 960
SW-620 275
CNS SF-268 1194
SF-295 1310
SF-539 605
SNB-19 644
SNB-75 194b
U251 420
Melanoma LOX IMVI 565
MALME-3M 86
M14 489
MDA-MB-435 341
SK-MEL-2 989
SK-MEL-28 406
SK-MEL-5 243
UACC-257 370
UACC-62 301
Ovarian IGROV1 167
OVCAR-3 3600
OVCAR-4 1270b
OVCAR-5 1120
OVCAR-8 499
NCI/ADR-RES 4000
SK-OV-3 363
Renal 786-0 2400
A498 365
ACHN 1150
CAKI-1 2330b
RXF 393 518
SN12C 2190
TK-10 795
UO-31 775
Prostate PC-3 917
DU-145 1016
Breast MCF7 440
MDA-MB-231/ATCC 1000
HS 578T 1022
BT-549 1945
MDA-MB-468 194
T-47D 45b
a GI50 ¼ concentration to achieve 50% inhibition (National Cancer
Institute, NCI); mean value of two runs. b One run. c Non small cell lung.
1832 | Med. Chem. Commun., 2014, 5, 1829–1833
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View Article OnlineBy contrast, when its ability to aﬀect vasculogenesis was
tested, compound 6 was less eﬀective than its single compound
equivalent, Semaxanib. Its major eﬀect was to inhibit Eg7
expression, a marker for angiogenisis, in the heart in a dose
dependent manner. Expression in intersomitic vessels (black
arrows, Fig. 5d) was aﬀected to a lesser extent. The failure of the
Eg7-expressing vascular endothelial cells to form tubes is also
apparent in the presence of compound 6; this can be seen when
their punctate staining (blue arrow, Fig. 5d) is compared with
the uninterrupted tube of the posterior cardinal vein present in
control embryos (Fig. 5a). Eg7 is expressed in vascular endo-
thelial cells and is directly activated by VEGFR2. The red arrow
shows the absence of Eg7 in the heart as concentrations were
increased and the black arrow shows its absence from the
intersomitic vessels. The blue arrow shows that the endothelial
cells that normally form the posterior cardinal vein have failed
to form a tube.
We tested the eﬀect on cell viability of dose-dependent
incubation for 72 h of MDA-MB231 cells with either a 1 : 1
mixture of SAHA (IC50 of SAHA in MDA-MB231 cells is 1.8 mM)32
and the kinase inhibitor 3b or the hybrid molecule 6 in a MTT
assay.33 As shown in Fig. 6 the mixture displays a dose–response
U-shaped curve with a maximal eﬀect equal to about 10 mM and
a reversion to 70% of cell viability at the highest concentration
used (i.e. 200 mM). Such U-shaped curves (hormesis) have
precedence in anticancer assays.34 On the other hand, the
hybrid drug shows a sigmoidal response with an IC50 ¼ 29 mM
and a reduction of cell survival down to ca. 30% vs. control at
200 mM concentration.
The hybrids were tested in a NCI single-dose in vitro assay,
with compound 6 being selected for repeat dosing over a ve-
dose range (Table 4) where it exhibited generally sub-
micromolar GI50 values, with notable ndings (all duplicate
averaged values) including the leukemia cell line, CCRF-CEM
(GI50 ¼ 102 nM), the NSCL cell line NCI-H522 (GI50 ¼ 87 nM)
and the melanoma cell line MALME-3M (GI50 ¼ 86 nM).
Conclusions
Compound 6 is an eﬀective dual-action hybrid. Its promising
preliminary data, notably in biochemical and in vitro assays as
well as in the NIH cell line, render it an eﬀective potential
chemical probe for angiogenisis.35,36 Current studies are aimed
at exploring further SAR in these hybrids with regard to HDAC
isoform37,38 and kinase selectivity39 as well as improving their
physiochemical properties,40 and will be reported in due course.
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